Spontaneous recovery of list 1 responses in the A-B, A'-C paradigm.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Hamilton.
Explore the source record for details and available documents.
BACKGROUND: The diagnosis of Helicobacter pylori is an essential element in the management of many common gastrointestinal pathologies. Previously diagnosis was dependent on the availability of endoscopic biopsy samples. The advent of non invasive assays such as the C13Urea breath test and Elisa serology have enabled diagnosis and treatment to be undertaken in the primary care setting. The isolation of Helicobacter pylori antigen from stool has led to the development of a new non-invasive test. AIM: A prospective study was designed to assess and compare the performance of Premier Platinum HpSA with current gold standard tests. METHODS: Consecutive patients undergoing a gastroscopy for investigation of dyspepsia at the Meath and Adelaide hospitals were enrolled. At endoscopy gastric biopsies were taken for histology, microbiology and rapid urease testing. In addition all subjects had C13UBT, serology and stool tests performed. Individuals who were H. pylori positive received standard proton pump inhibitor based triple therapy. Following treatment all tests, apart from serology were repeated. RESULTS: 54 patients were enrolled, 46 per cent were H. pylori positive. HpSA had a sensitivity and specificity and positive and negative predicted values of 96 per cent, 75 per cent and 80.6 per cent, 75.8 per cent respectively and compared favourably with all other tests. The sensitivity and specificities of the other tests were, histology 79.2 per cent and 100 per cent, culture 68 per cent and 100 per cent, rapid urease test 75 per cent and 100 per cent, serology 75 per cent and 96 per cent and C13 urea breath test 100 per cent and 96.6 per cent. CONCLUSION: The detection of H. pylori antigen in stool by means of a HpSA assay is a new and effective non-invasive means of diagnosis which can be performed in a routine laboratory setting. It is simple to perform and has possible advantages over other non-invasive tests, detecting actual antigen indicating current active infection.
In the past, problems associated with the prolonged maintenance of a patient with a central venous catheter (CVC), inserted for the administration of antibiotics, chemotherapy, intravenous (i.v.) fluid replacement of i.v. alimentation, have limited the duration that such catheters can remain in situ. This article highlights the necessity for and increasing importance of accurate patient assessment before catheter insertion for the long-term care and maintenance of individual i.v. devices. CVCs that may once have had a limited lifespan as a result of thrombosis, infection and eventual lack of suitable venous access, are increasingly being maintained in a satisfactory functional condition for long periods, ranging from many months to years.
Explore the source record for details and available documents.
The efficacy and safety of cefprozil at two dose levels were evaluated in 110 patients with acute uncomplicated bacterial sinusitis in an uncontrolled, noncomparative, Phase II trial. Ninety patients received 250 mg of cefprozil (low-dose group) and 20 patients received 500 mg of cefprozil (high-dose group) every 12 hours for ten days. Evaluable patients had symptoms consistent with acute sinusitis, pathogens isolated at pretreatment susceptible to cefprozil, and a radiograph positive for sinusitis within 48 hours before treatment. A satisfactory clinical response was achieved in 34 of 39 evaluable patients (87%) in the low-dose group and in all 16 evaluable patients (100%) in the high-dose group. Pathogens were eradicated in 35 of 39 patients (90%) in the low-dose group and in 15 of 16 patients (94%) in the high-dose group. A total of 140 of 155 pathogens (90%) isolated pretreatment were susceptible to cefprozil. Six patients (7%) in the low-dose group and one patient (5%) in the high-dose group reported at least one adverse clinical event.
Explore the source record for details and available documents.
Historically, central venous tunnelled lines have been inserted by senior medical officers, usually in the operating theatre under general anaesthetic. This method of line placement is applied to patients requiring lines for total parenteral nutrition (TPN), chemotherapy and long-term antibiotic therapy. Since February, 1991, following extensive training, a clinical nurse specialist (CNS) has taken on this role and has expanded the service to include a central line insertion service (LIS) throughout the Oxfordshire district.